DIAL-SDM: Shared Decision Making in Dialysis

Sponsor
University of Rochester (Other)
Overall Status
Recruiting
CT.gov ID
NCT04392440
Collaborator
National Institutes of Health (NIH) (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)
60
1
2
24
2.5

Study Details

Study Description

Brief Summary

Older patients ≥65 years with chronic kidney disease (CKD) face challenges in decision making about dialysis. These patients report little effort by physicians to elicit treatment preferences, discuss prognoses, or explain the burdens/benefits of dialysis options including conservative management. Older patients with CKD often prefer maintaining the quality of life over prolonging life, and many regret their decision to start dialysis: nearly one quarter withdraw from dialysis each year. Shared dialysis decision-making requires active engagement between nephrologists and patients to align patient, caregiver, and physician communication around common goals. The proposed study is a pilot randomized cluster trial of a dialysis shared decision-making (DIAL-SDM) intervention for nephrologists (n=20) and their patients ≥65 years old (n=60) with an estimated glomerular filtration rate (eGFR) of ≤ 20 ml/min/ /1.73 m2. Nephrologists in the Intervention Group will receive 3 communication training sessions, delivered by a standardized patient instructor (SPI) who enact clinical scenarios and offer feedback. In parallel, patients (and caregivers, if available) will receive 2 coaching sessions provided by health coaches, who will explore each patient's relevant contextual information (values, preferences, and goals), and help them identify and practice important questions for their nephrologist. Nephrologists in the Control Group will provide their patients with usual care. The study outcomes will be assessed during two nephrology office visits and at 6 months.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: DIAL-SDM
  • Other: usual care
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Supportive Care
Official Title:
Pilot Testing of a Communication Intervention to Promote Shared Dialysis Decision Making in Older Patients With Chronic Kidney Disease (DIAL-SDM Trial)
Actual Study Start Date :
Feb 28, 2022
Anticipated Primary Completion Date :
Oct 30, 2023
Anticipated Study Completion Date :
Mar 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: intervention

Behavioral: DIAL-SDM
Communication intervention for nephrologists and coaching intervention for patients.

Other: control

Usual care

Other: usual care
regular nephrology care

Outcome Measures

Primary Outcome Measures

  1. Mean feasibility of DIAL-SDM intervention [Approximately 12 months]

    This outcome will be measure in 30 patients in the Intervention Group by the following measure. Feasibility of the Intervention Measure is a 4-item scale that measures the extent to which a new treatment, or an innovation, can be successfully used or carried out within a given agency or setting. Higher scores indicate greater feasibility. The score ranges from 0-20.

  2. mean acceptability of DIAL-SDM intervention [Approximately 12 months]

    This outcome will be measure in 30 patients in the Intervention Group by the following measures respectively. Acceptability of the Intervention Measure is a 4-item scale that measures the perception among implementation stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory. Higher scores indicate greater acceptability. The score ranges from 0-20.

  3. fidelity of DIAL-SDM intervention [Approximately 12 months]

    This outcome will be measured by looking at the fidelity in which the interventionists complete the intervention checklist after each visit for 30 patients in the Intervention Group. It will be reported as the number of checklists that are at least 90% complete.

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
For nephrologist:
  • Member of Strong nephrology group working at Strong Memorial Hospital

  • Treat patients with CKD

For patients:
  • Age ≥65 years old

  • Presence of advanced CKD stage 4 or 5 (i.e. e GFR ≤ 20 ml/min)

  • Patient's nephrologist is enrolled in the study, and has seen that nephrologist at least once

  • Speaks English

  • Have not attended a dialysis education class or met with the dialysis education coordinator.

  • Have not made a dialysis decision

For Caregivers:
  • Self-identified caregiver (per definition:"family member, partner, friend or someone else who is involved with your health care issues, for example, someone who you talk to about personal issues including medical decisions or who comes to doctor appointments with you. This person may also help with routine day-to-day activities, like transportation or paperwork.")

  • 21 years of age or older.

Exclusion Criteria:
For Nephrologists:
  • Expecting to leave in six months.
For Patients:
  • Patient has already been seen by a palliative care clinician or is enrolled in hospice

  • Is already on dialysis

  • Hospitalized at the time of recruitment

  • Cognitive impairment

  • Does not speak English

For Caregivers:
  • If Support is offered primarily in a professional role (e.g., clergy).

  • Cognitive impairment

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Rochester Rochester New York United States 14642

Sponsors and Collaborators

  • University of Rochester
  • National Institutes of Health (NIH)
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fahad Saeed, Assistant Professor, University of Rochester
ClinicalTrials.gov Identifier:
NCT04392440
Other Study ID Numbers:
  • STUDY00004907
  • K23DK121939
First Posted:
May 18, 2020
Last Update Posted:
Apr 6, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 6, 2022